Systemic inflammatory response syndrome associated with amifostine

Shaw, Peter J.; Bleakley, Marie

doi:10.1002/(sici)1096-911x(200004)34:4<309::aid-mpo25>3.0.co;2-x

Cited by 9 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient experienced SIRS about 6 hours after receiving the last of several doses. 16 The patient had a diffuse, nonspecific, erythematous macular rash that accompanied the fever, chills, and hypotension. With additional doses of amifostine, the rash worsened; when the drug was stopped, no further acute reactions occurred.…”

Section: Literature Reviewmentioning

confidence: 99%

Amifostine‐Induced Fever: Case Report and Review of the Literature

Boehme

Wilson

2004

Pharmacotherapy

View full text Add to dashboard Cite

Amifostine, also known as WR-2721 (S-2-(3-aminopropylamino)-ethylphosphorothioic acid), is an organic thiophosphate cytoprotective agent used to reduce the frequency of severe xerostomia in patients with cancer undergoing postoperative radiation of the head and neck. A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine. To our knowledge, this is the first case report that demonstrates the occurrence of fever with low-dose amifostine therapy without the manifestation of accompanying rash or hypotension. Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. Recognition of amifostine as the cause of this adverse event may prevent the cost and inconvenience of a hospital admission.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Amifostine‐Induced Fever: Case Report and Review of the Literature

Boehme

Wilson

2004

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Current Awareness

2000

Pharmacoepidem. Drug Safe.

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract